1. Home
  2. SEAT vs IFRX Comparison

SEAT vs IFRX Comparison

Compare SEAT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vivid Seats Inc.

SEAT

Vivid Seats Inc.

HOLD

Current Price

$6.76

Market Cap

60.6M

Sector

Industrials

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$2.11

Market Cap

66.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEAT
IFRX
Founded
2001
2007
Country
United States
Germany
Employees
768
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
60.6M
66.0M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
SEAT
IFRX
Price
$6.76
$2.11
Analyst Decision
Buy
Strong Buy
Analyst Count
8
4
Target Price
$18.06
$6.25
AVG Volume (30 Days)
92.9K
1.4M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.42
$0.71
52 Week High
$35.00
$2.20

Technical Indicators

Market Signals
Indicator
SEAT
IFRX
Relative Strength Index (RSI) 50.63 81.36
Support Level $6.08 $0.86
Resistance Level $7.85 N/A
Average True Range (ATR) 0.67 0.22
MACD -0.08 0.07
Stochastic Oscillator 31.30 90.31

Price Performance

Historical Comparison
SEAT
IFRX

About SEAT Vivid Seats Inc.

Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada and Japan. It operates in two segments namely marketplace and resale. Marketplace segment, act as an intermediary between ticket buyers, sellers, and partners through which company earn revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. Resale segment provides internal research and development support for Skybox and supplements ongoing efforts to deliver software and tools. Majority of revenue is from Marketplace segment.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: